▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3306 by analyst upside · 2026-09-27
ELV
Elevance Health, Inc.
Healthcare · Market Cap $86B · P/E 17.5x
ANALYST PRICE TARGET
+14.0%
implied upside to consensus target
Current Price $396.09
Consensus Target $451.38
Bull Target $492.0
Bear Target $393.0
Analysts Covering 21
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
11
Hold
8
Sell
0
52-Week Low $274.84
52-Week High $436.24
YTD Return +13.4%
FUNDAMENTALS
Market Cap $86B
P/E Ratio (TTM) 17.5x
Forward P/E 13.4x
EPS (TTM) $22.62
PEG Ratio 1.30
Dividend Yield 1.74%
Revenue (TTM) $201.1B
Profit Margin 2.5%
52-WEEK RANGE
52-Week Low $274.84
52-Week High $436.24
Current Price $396.09
Bear Target $393.0
Bull Target $492.0
● Now $396.09 ● Target $451.38
TRADING DATA
Avg Volume 1.2M
YTD Return +13.4%
Analyst Count 21
Consensus Buy
Upside to Target +14.0%
Last Updated 2026-09-27

ANALYST SUMMARY

Elevance Health, Inc. (ELV) is currently trading at $396.09 with a Wall Street consensus price target of $451.38, implying potential upside of 14.0% over the next 12 months. 21 analysts currently cover ELV, with a consensus rating of Buy - 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $492.0, while the most cautious has a target of $393.0.

ELV operates in the Healthcare sector with a market capitalisation of $86B. The stock is up 13.4% year-to-date and is currently trading near the upper end of its 52-week range of $274.84 – $436.24.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ELV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Market Perform → Market Perform 2026-07-17 29% win rate (7 calls)
Bernstein - Reiterated
Outperform → Outperform 2026-07-17 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-07-16 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-07-16 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-07-16 62% win rate (8 calls)
Barclays - Reiterated
Overweight → Overweight 2026-07-16 Building track record
Baird - Reiterated
Neutral → Neutral 2026-07-16 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-07-14 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
63
out of 100
Coverage depth
24/30
Consensus clarity
25/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →